help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Published ahead of print on June 16, 2005, doi:10.1164/rccm.200410-1413OC
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
200410-1413OCv1
172/7/824    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Levy, B. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Levy, B. D.
American Journal of Respiratory and Critical Care Medicine Vol 172. pp. 824-830, (2005)
© 2005 American Thoracic Society
doi: 10.1164/rccm.200410-1413OC

Original Article

Diminished Lipoxin Biosynthesis in Severe Asthma

Bruce D. Levy, Caroline Bonnans, Eric S. Silverman, Lyle J. Palmer, Gautham Marigowda, Elliot Israel for the Severe Asthma Research Program, National Heart, Lung, and Blood Institute

Pulmonary and Critical Care Medicine and Partners Asthma Center, Department of Internal Medicine, Brigham and Women's Hospital, Harvard Medical School; Pulmonary Physiology Program, Harvard School of Public Health, Boston, Massachusetts; and Western Australian Institute for Medical Research, UWA Centre for Medical Research, University of Western Australia, Perth, Australia

Correspondence and requests for reprints should be addressed to Bruce D. Levy, M.D., Pulmonary and Critical Care Medicine, PBB-Clinics-3, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115. E-mail: blevy{at}partners.org

Rationale and Objectives: Severe asthma is characterized by increased airway inflammation that persists despite therapy with corticosteroids. It is not, however, merely an exaggeration of the eosinophilic inflammation that characterizes mild to moderate asthma; rather, severe asthma presents unique features. Although arachidonic acid metabolism is well appreciated to regulate airway inflammation and reactivity, alterations in the biosynthetic capacity for both pro- and antiinflammatory eicosanoids in severe asthma have not been determined.

Methods: Patients with severe asthma were identified according to National Heart, Lung, and Blood Institute Severe Asthma Research Program criteria. Samples of whole blood from individuals with severe or moderate asthma were assayed for biosynthesis of lipoxygenase-derived eicosanoids.

Measurements and Main Results: The counterregulatory mediator lipoxin A4 was detectable in low picogram amounts, using a novel fluorescence-based detection system. In activated whole blood, mean lipoxin A4 levels were decreased in severe compared with moderate asthma (0.4 [SD 0.4] ng/ml vs. 1.8 [SD 0.8] ng/ml, p = 0.001). In sharp contrast, mean levels of prophlogistic cysteinyl leukotrienes were increased in samples from severe compared with moderate asthma (112.5 [SD 53.7] pg/ml vs. 64.4 [SD 24.8] pg/ml, p = 0.03). Basal circulating levels of lipoxin A4 were also decreased in severe relative to moderate asthma. The marked imbalance in lipoxygenase-derived eicosanoid biosynthesis correlated with the degree of airflow obstruction.

Conclusions: Mechanisms underlying airway responses in severe asthma include underproduction of lipoxins. This is the first report of a defect in lipoxin biosynthesis in severe asthma, and suggests an alternative therapeutic strategy that emphasizes natural counterregulatory pathways in the airways.

Key Words: biosynthesis • chromatography, eicosanoids • high-pressure liquid • inflammation mediators




This article has been cited by other articles:


Home page
 Am. J. Pathol.Home page
S.-H. Wu, P.-Y. Liao, P.-L. Yin, Y.-M. Zhang, and L. Dong
Elevated Expressions of 15-Lipoxygenase and Lipoxin A4 in Children with Acute Poststreptococcal Glomerulonephritis
Am. J. Pathol., January 1, 2009; 174(1): 115 - 122.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
V. Starosta, K. Pazdrak, I. Boldogh, T. Svider, and A. Kurosky
Lipoxin A4 Counterregulates GM-CSF Signaling in Eosinophilic Granulocytes
J. Immunol., December 15, 2008; 181(12): 8688 - 8699.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
A. Planaguma, S. Kazani, G. Marigowda, O. Haworth, T. J. Mariani, E. Israel, E. R. Bleecker, D. Curran-Everett, S. C. Erzurum, W. J. Calhoun, et al.
Airway Lipoxin A4 Generation and Lipoxin A4 Receptor Expression Are Decreased in Severe Asthma
Am. J. Respir. Crit. Care Med., September 15, 2008; 178(6): 574 - 582.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Cell Mol. Bio.Home page
C. Thompson, S. McMahon, Y. Bosse, C. M. Dubois, J. Stankova, and M. Rola-Pleszczynski
Leukotriene D4 Up-Regulates Furin Expression through CysLT1 Receptor Signaling
Am. J. Respir. Cell Mol. Biol., August 1, 2008; 39(2): 227 - 234.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
N. C. Mishra, J. Rir-sima-ah, R. J. Langley, S. P. Singh, J. C. Pena-Philippides, T. Koga, S. Razani-Boroujerdi, J. Hutt, M. Campen, K. C. Kim, et al.
Nicotine Primarily Suppresses Lung Th2 but Not Goblet Cell and Muscle Cell Responses to Allergens
J. Immunol., June 1, 2008; 180(11): 7655 - 7663.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
B. D. Levy, N. W. Lukacs, A. A. Berlin, B. Schmidt, W. J. Guilford, C. N. Serhan, and J. F. Parkinson
Lipoxin A4 stable analogs reduce allergic airway responses via mechanisms distinct from CysLT1 receptor antagonism
FASEB J, December 1, 2007; 21(14): 3877 - 3884.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
O. Haworth and B. D. Levy
Endogenous lipid mediators in the resolution of airway inflammation
Eur. Respir. J., November 1, 2007; 30(5): 980 - 992.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
N. L. Rao, P. J. Dunford, X. Xue, X. Jiang, K. A. Lundeen, F. Coles, J. P. Riley, K. N. Williams, C. A. Grice, J. P. Edwards, et al.
Anti-Inflammatory Activity of a Potent, Selective Leukotriene A4 Hydrolase Inhibitor in Comparison with the 5-Lipoxygenase Inhibitor Zileuton
J. Pharmacol. Exp. Ther., June 1, 2007; 321(3): 1154 - 1160.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Cell Mol. Bio.Home page
C. Bonnans and B. D. Levy
Lipid Mediators as Agonists for the Resolution of Acute Lung Inflammation and Injury
Am. J. Respir. Cell Mol. Biol., February 1, 2007; 36(2): 201 - 205.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
B. D. Levy, P. Kohli, K. Gotlinger, O. Haworth, S. Hong, S. Kazani, E. Israel, K. J. Haley, and C. N. Serhan
Protectin D1 Is Generated in Asthma and Dampens Airway Inflammation and Hyperresponsiveness
J. Immunol., January 1, 2007; 178(1): 496 - 502.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Cell Mol. Bio.Home page
C. Thompson, A. Cloutier, Y. Bosse, M. Thivierge, C. L. Gouill, P. Larivee, P. P. McDonald, J. Stankova, and M. Rola-Pleszczynski
CysLT1 Receptor Engagement Induces Activator Protein-1- and NF-{kappa}B-Dependent IL-8 Expression
Am. J. Respir. Cell Mol. Biol., December 1, 2006; 35(6): 697 - 704.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
S. E. Wenzel and R. Covar
Update in asthma 2005.
Am. J. Respir. Crit. Care Med., April 1, 2006; 173(7): 698 - 706.
[Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
J. L. Wallace
Commonality of Defensive Roles of COX-2 in the Lung and Gut
Am. J. Pathol., April 1, 2006; 168(4): 1060 - 1063.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 2005 American Thoracic Society 		  ATS State of the Art Course 2008